Abstract
Tardive dyskinesia is a syndrome of abnormal, involuntary movements, which occurs as a complication of long-term neuroleptic therapy. The pathophysiology of this potentially irreversible syndrome is still an enigma. The objective of the present study was to elucidate the role of N-methyl-D-aspartate (NMDA) receptor involvement in neuroleptic-induced orofacial dyskinesia in rats. Animals chronically treated with haloperidol for a period of 40 weeks exhibited significantly more vacuous chewing movements (VCMs), as compared to vehicle-treated controls. In a series of acute experiments, rats received: amantadine (10, 20, and 40 mg/kg i.p.), a low-affinity, uncompetitive NMDA-receptor antagonist (open channel blocker); dextrorphan (5, 10, and 20 mg/kg i.p.), an NMDA receptor channel antagonist; ifenprodil (2.5, 5, and 10 mg/kg i.p.), a noncompetitive allosteric NMDA receptor antagonist acting at the polyamine site; and Ro 25-6981 (2.5, 5, and 10 mg/kg i.p.), a potent and selective blocker of NMDA receptors which contain the NR2B subunit. All the drugs tested, except dextrorphan, reduced VCMs and tongue protrusions with varying efficacies and side effects profiles. Ro 25-6981 was found significantly more potent than amantadine and if...Continue Reading
References
Oct 23, 1992·Science·S Nakanishi
May 22, 1992·Science·H MonyerP H Seeburg
Sep 1, 1992·Drugs·M A Rogawski
Jul 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·J L MontastrucA Rascol
Jul 1, 1992·Annals of Neurology·N M RupniakC D Marsden
Jan 9, 1989·Brain Research·R G RobertsonA R Crossman
May 8, 1985·European Journal of Pharmacology·J ChurchS C Berry
Jan 1, 1994·European Journal of Pharmacology·K HashimotoE D London
Oct 1, 1993·Clinical Neuropharmacology·B Gomez-Mancilla, P J Bédard
Oct 1, 1995·Neuropharmacology·C G ParsonsW Danysz
May 1, 1996·Annals of Neurology·S M Papa, T N Chase
Sep 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Oct 1, 1996·British Journal of Pharmacology·O A AndreassenH A Jøorgensen
Oct 1, 1996·Psychopharmacology·M F EganT M Hyde
May 8, 1998·Journal of Neurochemistry·V MutelJ G Richards
May 22, 1998·Neurology·L Verhagen MetmanT N Chase
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·L Verhagen MetmanT N Chase
Jun 18, 1998·Psychopharmacology·T HashimotoC A Tamminga
Jul 23, 1998·Neurology·L Verhagen MetmanT N Chase
Nov 11, 1999·Archives of Neurology·L V MetmanT N Chase
Jan 14, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·L V MetmanT N Chase
Jun 27, 2000·Brain : a Journal of Neurology·C S LeeA Björklund
Apr 1, 1997·Journal of Clinical Psychopharmacology·S AngusN M Schneider
Sep 19, 2000·Journal of Neurology·T N ChaseS Konitsiotis
Jun 16, 2001·European Journal of Pharmacology·P S Naidu, S K Kulkarni
May 30, 2002·Neuroscience and Biobehavioral Reviews·Peter TurroneJosé N Nobrega
Sep 11, 2002·Neurology·L Verhagen MetmanT N Chase
Nov 19, 2003·Neuroscience·O A AndreassenH A Jørgensen
Apr 15, 2004·Experimental Neurology·Peter-Andreas LöschmannThomas Klockgether
Oct 28, 2004·Biochemical Society Transactions·C Fiorentini, C Missale
Citations
Oct 31, 2007·Neurotoxicity Research·G ColpoM E Burger
Sep 23, 2010·Psychopharmacology·Jennifer E MurrayRick A Bevins
Aug 1, 2009·Neurotoxicity Research·Raquel Cristine Silva BarcelosMarilise Escobar Bürger
Jul 27, 2012·Translational Psychiatry·S A IvanovaB Wilffert
Dec 3, 2010·Clinical Neuropharmacology·Sofia PappaSpiridon Konitsiotis
Apr 7, 2007·Journal of Clinical Psychopharmacology·Yeşim YetimalarMustafa Başoğlu
Mar 3, 2011·Journal of Clinical Psychopharmacology·Yesim Yetimalar BeckmannYeliz Çiftçi
Apr 17, 2012·Behavioural Brain Research·Susan E BachusJulie Nealon Minton
Mar 2, 2011·Behavioural Brain Research·Fabiola TrevizolMarilise E Bürger
Sep 18, 2012·Brain Research Bulletin·Kyoji SekiguchiYoshio Kase
Mar 14, 2012·European Journal of Pharmacology·Sotirios MaranisSpiridon Konitsiotis
May 28, 2020·Behavioural Pharmacology·Anna Maria Szota, Jørgen Scheel-Krüger